非布索坦上市没？

There should be no gout patient who doesn’t know (feburic), which is transliterated as febuxostat. So, is febuxostat on the market?

Febuxostat is now on the market!

It was approved for marketing by European EMEA in October 2008, with the trade name "Adenuric".

In February 2009, the US FDA approved it for sale under the trade name "ULORIC".

In the 2012 American College of Rheumatology Gout Guidelines, febuxostat was recommended as a Class A recommendation for drug treatment of patients with hyperuricemia and gout, which is also the first-line drug choice.

In June 2013, the State Food and Drug Administration of China approved febuxostat for marketing in China. 

Febuxostat effectively reduces blood uric acid levels in patients with hyperuricemia to below the recommended level of 6.0 mg/dL and is well tolerated by patients with mild to moderate renal impairment without dose adjustment. It is estimated that the number of people suffering from hyperuricemia in Japan is around 16 million.

Teijin Pharmaceutical discovered febuxostat as early as 1991. The drug is the first non-purine selective inhibitor of xanthine oxidase. Its chemical structure is different from allopurinol, which has been used as a standard treatment for hyperuricemia for more than 40 years.

In addition, some people think that febuxostat is an effective drug for the treatment of gout. In fact, gout is a group of metabolic diseases. Febuxostat only lowers blood uric acid and prevents gout attacks. However, the original drug recommended by doctors, allopurinol, has an allergic risk of about 1.5%. Severe cases may cause fatal allergies, and there is also a 1.2% risk of liver damage. The advantages of febuxostat in these two aspects are obviously better than that of allopurinol, and people have high hopes for febuxostat to replace allopurinol. However, patients should use it under the guidance of a doctor because febuxostat has risk factors for liver damage and cardiovascular disease.

At present, it has become the first choice of professional rheumatology and immunology doctors and the "miracle drug" that patients take seriously.